The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations

ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations

September 24, 2015 • By American College of Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—The American College of Rheumatology (ACR) has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA). The guideline was developed with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network. It summarizes recommendations for both pharmacologic and non-pharmacologic treatments, including rehabilitation, management of patients with comorbid conditions, use of certain surgeries and approaches to patient monitoring.

You Might Also Like
  • 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

“The ACR’s primary objective was to provide recommendations on optimal treatment for patients with AS and non-radiographic axial SpA that were based on quality evidence and took into consideration patient values and preferences,” said Michael Ward, MD, MPH, an investigator for the National Institutes of Health who served as principal investigator for the guideline project. “While the guideline does not cover all aspects of spondyloarthritis management, it provides a foundation based on the current best-available evidence.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In addition to covering a broad spectrum of treatment options, the guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (called GRADE) approach—a system recognized for transparency and for rating both the quality of available evidence and the strength of recommendations made. Important features of this method include the specification of patient groups, interventions, competing treatment alternatives and outcomes; grading the quality of the evidence used; and basing recommendation strength on evidence quality, balance of benefits and harms, patient preference of treatment options, as well as clinical experience and expertise.

Each recommendation is designated as being strongly for, conditionally for, conditionally against, or strongly against. Recommendations that were strongly for a given treatment signified that almost all patients would choose to receive the intervention and clinicians could expect it to be accepted by most patients to whom it is offered. Recommendations that were conditionally for a specified treatment signified that most patients would likely choose the intervention, but a sizable majority may not, and education and shared decision-making should play a large role. On the opposite end, conditional recommendations in opposition to an intervention signified that only a small a minority of patients would choose it, and education and shared decision-making would be important. Finally, strong recommendations in opposition to a treatment option signified interventions that most patients should neither receive nor be offered.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The recommendations are divided into five categories:

  • Recommendations for the treatment of patients with active AS (pharmacologic and rehabilitation)
  • Recommendations for the treatment of patients with stable AS (pharmacologic and rehabilitation)
  • Recommendations for the treatment of patients with either active or stable AS
  • Recommendations for the treatment of patients with AS and specific impairments or comorbidities (such as advanced hip arthritis, severe kyphosis, acute iritis, and inflammatory bowel disease)
  • Education and preventive care recommendations; and
  • Recommendations for the treatment of patients with non-radiographic axial SpA.

Each category contains several recommendations pertaining to pharmacologic and non-pharmacologic interventions, followed by supporting evidence and rationale.

Pages: 1 2 | Single Page

Filed Under: Conditions, From the College, Spondyloarthritis

You Might Also Like:
  • 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)